Log In
Print
BCIQ
Print
Print this Print this
 

RX-3117

  Manage Alerts
Collapse Summary General Information
Company Rexahn Pharmaceuticals Inc.
DescriptionNext-generation oral nucleoside analog that is activated by uridine cytidine kinase and inhibits DNA and RNA synthesis and mediates the down-regulation of DNA (cytosine-5-)-methyltransferase 1 (DNMT1)
Molecular Target DNA methyltransferase
Mechanism of ActionDNA methyltransferase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today